Detection and Characterization of Cancer Cells and Pathogenic Bacteria Using Aptamer-Based Nano-Conjugates

Gedi, Vinayakumar; Kim, Young‐Pil

doi:10.3390/s141018302

Cited by 39 publications

(22 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas several problem-oriented reviews discuss antibacterial or antiviral aptamers and their applications (Gedi & Kim, 2014; Ozalp et al, 2013; Shum et al, 2013; Zimbres et al, 2013), this review tends to systemize recent data concerning aptamers selected against viruses, bacteria, and unicellular parasites and their potential therapeutic and diagnostic applications.…”

Section: Introductionmentioning

confidence: 99%

Aptamers against pathogenic microorganisms

Davydova

Vorobjeva

Pyshnyi

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

An important current issue of modern molecular medicine and biotechnology is the search for new approaches to early diagnostic assays and adequate therapy of infectious diseases. One of the promising solutions to this problem might be a development of nucleic acid aptamers capable of interacting specifically with bacteria, protozoa, and viruses. Such aptamers can be used for the specific recognition of infectious agents as well as for blocking of their functions. The present review summarizes various modern SELEX techniques used in this field, and of several currently identified aptamers against viral particles and unicellular organisms, and their applications. The prospects of applying nucleic acid aptamers for the development of novel detection systems and antibacterial and antiviral drugs are discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Aptamers against pathogenic microorganisms

Davydova

Vorobjeva

Pyshnyi

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

show abstract

“…Hence, aptamers are stable over a wider range of ionic strengths, pH, and temperature. Besides that, aptamers are non‐toxic and non‐immunogenic . The generation of aptamers by SELEX allows aptamers to be chemically synthesized using simple assays which are inexpensive to scale up .…”

Section: Uniqueness Of Aptamers As Targeting Elementsmentioning

confidence: 99%

Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation

Jeevanandam

Tan

Danquah

et al. 2020

Biotechnology Journal

View full text Add to dashboard Cite

Theranostics cover emerging technologies for cell biomarking for disease diagnosis and targeted introduction of drug ingredients to specific malignant sites. Theranostics development has become a significant biomedical research endeavor for effective diagnosis and treatment of diseases, especially cancer. An efficient biomarking and targeted delivery strategy for theranostic applications requires effective molecular coupling of binding ligands with high affinities to specific receptors on the cancer cell surface. Bioaffinity offers a unique mechanism to bind specific target and receptor molecules from a range of non‐targets. The binding efficacy depends on the specificity of the affinity ligand toward the target molecule even at low concentrations. Aptamers are fragments of genetic materials, peptides, or oligonucleotides which possess enhanced specificity in targeting desired cell surface receptor molecules. Aptamer–target binding results from several inter‐molecular interactions including hydrogen bond formation, aromatic stacking of flat moieties, hydrophobic interaction, electrostatic, and van der Waals interactions. Advancements in Systematic Evolution of Ligands by Exponential Enrichment (SELEX) assay has created the opportunity to artificially generate aptamers that specifically bind to desired cancer and tumor surface receptors with high affinities. This article discusses the potential application of molecular dynamics (MD) simulation to advance aptamer‐mediated receptor targeting in targeted cancer therapy. MD simulation offers real‐time analysis of the molecular drivers of the aptamer‐receptor binding and generate optimal receptor binding conditions for theranostic applications. The article also provides an overview of different cancer types with focus on receptor biomarking and targeted treatment approaches, conventional molecular probes, and aptamers that have been explored for cancer cells targeting.

show abstract

“…Aptamers possess desirable biophysical and biochemical properties as a new class of targeting elements. These properties include high affinity and specificity toward target cells and biomolecules, small size for effective hydrodynamics and cyto‐membrane penetrations, ease of generation and synthesis, ease of biochemical labeling and molecular formulation, and high chemical and thermal stability . The approval of the first aptameric biological drug, Pegatanib, in 2004 by U.S Food and Drug Administration (FDA) has incited significant research interests on the medical applications of aptamers.…”

Section: Introductionmentioning

confidence: 99%

“…These properties include high affinity and specificity toward target cells and biomolecules, small size for effective hydrodynamics and cyto-membrane penetrations, ease of generation and synthesis, ease of biochemical labeling and molecular formulation, and high chemical and thermal stability. 3,5 The approval of the first aptameric biological drug, Pegatanib, in 2004 by U.S Food and Drug Administration (FDA) has incited significant research interests on the medical applications of aptamers. There are various aptamer-based drug designs undergoing clinical trials, and these include AS1411 nucleolin-specific aptamer for acute myeloid leukemia and REG1-targeting aptamer for coronary artery disease.…”

Section: Introductionmentioning

confidence: 99%

Biophysical characterization of layer‐by‐layer synthesis of aptamer‐drug microparticles for enhanced cell targeting

Tan

Danquah

Sidhu

et al. 2017

Biotechnology Progress

View full text Add to dashboard Cite

Targeted delivery of drug molecules to specific cells in mammalian systems demonstrates a great potential to enhance the efficacy of current pharmaceutical therapies. Conventional strategies for pharmaceutical delivery are often associated with poor therapeutic indices and high systemic cytotoxicity, and this result in poor disease suppression, low surviving rates, and potential contraindication of drug formulation. The emergence of aptamers has elicited new research interests into enhanced targeted drug delivery due to their unique characteristics as targeting elements. Aptamers can be engineered to bind to their cognate cellular targets with high affinity and specificity, and this is important to navigate active drug molecules and deliver sufficient dosage to targeted malignant cells. However, the targeting performance of aptamers can be impacted by several factors including endonuclease-mediated degradation, rapid renal filtration, biochemical complexation, and cell membrane electrostatic repulsion. This has subsequently led to the development of smart aptamer-immobilized biopolymer systems as delivery vehicles for controlled and sustained drug release to specific cells at effective therapeutic dosage and minimal systemic cytotoxicity. This article reports the synthesis and in vitro characterization of a novel multi-layer co-polymeric targeted drug delivery system based on drug-loaded PLGA-Aptamer-PEI (DPAP) formulation with a stage-wise delivery mechanism. A thrombin-specific DNA aptamer was used to develop the DPAP system while Bovine Serum Albumin (BSA) was used as a biopharmaceutical drug in the synthesis process by ultrasonication. Biophysical characterization of the DPAP system showed a spherical shaped particulate formulation with a unimodal particle size distribution of average size ∼0.685 µm and a zeta potential of +0.82 mV. The DPAP formulation showed a high encapsulation efficiency of 89.4 ± 3.6%, a loading capacity of 17.89 ± 0.72 mg BSA protein/100 mg PLGA polymeric particles, low cytotoxicity and a controlled drug release characteristics in 43 days. The results demonstrate a great promise in the development of DPAP formulation for enhanced in vivo cell targeting. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 34:249-261, 2018.

show abstract

Detection and Characterization of Cancer Cells and Pathogenic Bacteria Using Aptamer-Based Nano-Conjugates

Cited by 39 publications

References 137 publications

Aptamers against pathogenic microorganisms

Aptamers against pathogenic microorganisms

Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation

Biophysical characterization of layer‐by‐layer synthesis of aptamer‐drug microparticles for enhanced cell targeting

Contact Info

Product

Resources

About